
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
GENERAL COMMENTARY article
Front. Pharmacol. , 24 September 2015
Sec. Experimental Pharmacology and Drug Discovery
Volume 6 - 2015 | https://doi.org/10.3389/fphar.2015.00214
This article is part of the Research Topic Frontiers in the Pharmacological Manipulation of Intracellular cAMP Levels View all 18 articles
This article is a commentary on:
Impact of kinase activating and inactivating patient mutations on binary PKA interactions
A corrigendum on
Impact of kinase activating and inactivating patient mutations on binary PKA interactions
by Röck, R., Mayrhofer, J. E., Bachmann, V., and Stefan, E. (2015). Front. Pharmacol. 6:170. doi: 10.3389/fphar.2015.00170
Reason for Corrigendum:
There was a mistake in the figure legend for Figure 5 as published. The correct version of the figure legend (Figure 5B) appears below. The authors apologize for the mistake. This error does not change the scientific conclusions of the article in any way.
Figure 5. Impact of RIa mutations and cAMP elevation on PKA type I complexes. … (B) Following indicated modifications of RIa-F[1] sequences, combinations of wild type and mutant Rluc PCA tagged PKA subunits have been subjected to Rluc PCA measurements. The effect of isoproterenol (1 μM, 10 min; 48 h transient PCA reporter expression) on PKA complex formation has been determined (at least n = 3 independent experiments, ±SEM).
The original article was updated.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Keywords: molecular interactions, patient mutations, cAMP-dependent protein kinase A, protein-fragment complementation assay, GPCR, Carney complex, Acrodysostosis
Citation: Röck R, Mayrhofer JE, Bachmann V and Stefan E (2015) Corrigendum: Impact of kinase activating and inactivating patient mutations on binary PKA interactions. Front. Pharmacol. 6:214. doi: 10.3389/fphar.2015.00214
Received: 09 September 2015; Accepted: 14 September 2015;
Published: 24 September 2015.
Edited and reviewed by: Apostolos Zarros, University of Glasgow, UK
Copyright © 2015 Röck, Mayrhofer, Bachmann and Stefan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eduard Stefan,ZWR1YXJkLnN0ZWZhbkB1aWJrLmFjLmF0
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.